A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

NCT00246298 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class

Stopped OBI business decision not to complete any additional research in HIV.

Conditions

Interventions

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators